Tykerb Tablet
NDC Package 0078-0671-19
Package Information
Tykerb (lapatinib) tablets is tYKERB® is indicated in combination with:capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab.Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine.letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. This formulation utilizes a tablet delivery system. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-0671 and is authorized under FDA application NDA022059.
Identification & Billing
- RxCUI: 672149 - lapatinib 250 MG Oral Tablet
- RxCUI: 672149 - lapatinib 250 MG (as lapatinib ditosylate 398 MG) Oral Tablet
- RxCUI: 672152 - Tykerb 250 MG Oral Tablet
- RxCUI: 672152 - lapatinib 250 MG Oral Tablet [Tykerb]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0078 - Novartis Pharmaceuticals Corporation
- 0078-0671 - Tykerb
- 0078-0671-19 - 150 TABLET in 1 BOTTLE
- 0078-0671 - Tykerb
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0078-0671-19 identifies a specific commercial package of 150 tablet in 1 bottle of Tykerb, a human prescription drug labeled by Novartis Pharmaceuticals Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 150 billable units per package. This tablet is formulated for oral use and contains lapatinib ditosylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on August 03, 2016. The current certification is valid through December 31, 2027.
How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078067119. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 150 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.